Bank of America Corp DE Has $2.35 Million Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Bank of America Corp DE grew its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 938.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 170,543 shares of the biotechnology company's stock after buying an additional 154,127 shares during the period. Bank of America Corp DE owned 0.38% of Capricor Therapeutics worth $2,353,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in CAPR. Vanguard Group Inc. increased its position in Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 700,243 shares during the period. Geode Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock valued at $12,139,000 after purchasing an additional 241,279 shares during the period. Altium Capital Management LLC raised its stake in shares of Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after purchasing an additional 429,000 shares in the last quarter. Northern Trust Corp raised its stake in shares of Capricor Therapeutics by 43.3% during the fourth quarter. Northern Trust Corp now owns 384,157 shares of the biotechnology company's stock valued at $5,301,000 after purchasing an additional 116,086 shares in the last quarter. Finally, Black Diamond Financial LLC acquired a new stake in Capricor Therapeutics in the fourth quarter worth about $3,833,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CAPR shares. Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. Finally, Roth Capital began coverage on Capricor Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $31.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $35.50.

Capricor Therapeutics Trading Up 7.4%

Shares of NASDAQ CAPR traded up $0.91 during midday trading on Thursday, reaching $13.25. The company's stock had a trading volume of 2,045,590 shares, compared to its average volume of 1,664,524. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The company has a market cap of $605.22 million, a price-to-earnings ratio of -12.48 and a beta of 0.85. The company has a 50 day moving average price of $10.15 and a 200 day moving average price of $13.03.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The company had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same period in the prior year, the company posted ($0.31) EPS. Research analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.